Prevalence and concordance of early and sustained remission assessed by various validated indices in the early arthritis "ESPOIR" cohort

Joint Bone Spine

Volumn 81, Issue 5, 2014, Pages 409-415

  Hmamouchi, Ihsane ^a,b   Combe, Bernard ^a   Fautrel, Bruno ^c   Rincheval, Nathalie ^a   Lukas, Cédric ^a  

^a LAPEYRONIE HOSPITAL   (France)

^b MOHAMMED V UNIVERSITY   (Morocco)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

Early remission; Early rheumatoid arthritis; ESPOIR cohort; Remission criteria; Sustained remission

Indexed keywords

ADULT; ARTHRITIS; ARTICLE; COHORT ANALYSIS; DAS28; DISEASE ACTIVITY SCORE; DISEASE CLASSIFICATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PREVALENCE; REMISSION; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; SUSTAINED REMISSION; VALIDATION STUDY; AGED; ARTHRITIS, RHEUMATOID; FRANCE; HEALTH STATUS INDICATOR; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; FRANCE; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; REMISSION INDUCTION;

EID: 84926310925     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2014.02.007     Document Type: Article

References (31)

1. Sokka T. Long-term outcomes of rheumatoid arthritis. Current Opin Rheumatol 2009, 21:284-290.
2. Schoels M., Knevel R., Aletaha D., et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010, 69:638-643.
3. Smolen J.S., Aletaha D., Bijlsma J.W., et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010, 69:631-637.
4. Prevoo M.L., van THof M.A., van Kuper H.H., et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48.
5. Aletaha D., Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005, 23:100-108.
6. Felson D.T., Smolen J.S., Wells G., et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011, 63:573-586.
7. Shahouri S.H., Michaud K., Mikuls T.R., et al. Remission of rheumatoid arthritis in clinical practice: application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria. Arthritis Rheum 2011, 63:3204-3215.
8. Zhang B., Combe B., Rincheval N., et al. Validation of ACR/EULAR definition of remission in rheumatoid arthritis from RA practice: the ESPOIR cohort. Arthritis Res Ther 2012, 14:R156.
9. Jayakumar K., Norton S., Dixey J., et al. Sustained clinical remission in rheumatoid arthritis: prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDS. Rheumatology 2012, 51:169-175.
10. Svensson B., Andersson M.L., Bala S.V., et al. Long-term sustained remission in a cohort study of patients with rheumatoid arthritis: choice of remission criteria. BMJ Open 2013, 3:e003554.
11. Prince F.H., Bykerk V.P., Shadick N.A., et al. Sustained rheumatoid arthritis remission is uncommon in clinical practice. Arthritis Res Ther 2012, 14:R68.
12. Combe B., Benessiano J., Berenbaum F., et al. ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients. Joint Bone Spine 2007, 74:440-445.
13. Lukas C., Combe B., Ravaud P., et al. Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: data from the étude et suivi des polyarthrites indifférenciées récentes (study and follow-up of early undifferentiated polyarthritis). Arthritis Rheum 2011, 63:1804-1811.
14. Devauchelle-Pensec V., Josseaume T., Samjee I., et al. Ability of oblique foot radiographs to detect erosions in early arthritis: results in the ESPOIR cohort. Arthritis Rheum 2008, 59:1729-1734.
15. van der Heijde D.M., van Riel P.L., Nuver-Zwart I.H., et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989, 1:1036-1038.
16. Mouterde G., Lukas C., Logeart I., et al. Predictors of radiographic progression in the ESPOIR cohort: the season of first symptoms may influence the short-term outcome in early arthritis. Ann Rheum Dis 2011, 70:1251-1256.
17. Klarenbeek N.B., Koevoets R., van der Heijde D.M., et al. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis. Ann Rheum Dis 2011, 70:1815-1821.
18. Mäkinen H., Hannonen P., Sokka T. Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomised clinical trials for the rate of remission. Clin Exp Rheumatol 2006, 24. [S-22-8].
19. Khanna D., Oh M., Furst D.E., et al. Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort. Arthritis Rheum 2007, 57:440-447.
20. Mierau M., Schoels M., Gonda G., et al. Assessing remission in clinical practice. Rheumatology 2007, 46:975-979.
21. Landewe R., van der Heijde D.M., Voskuyl A., et al. Condensed 28-joint counts jeopardise the construct validity of DAS28 remission: a comparison with the original DAS. Arthritis Rheum 2004, 50:S457.
22. Makinen H., Kautiainen H., Hannonen P., et al. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?. Ann Rheum Dis 2005, 64:1410-1413.
23. van der Heijde D., Klareskog L., Boers M., et al. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis 2005, 64:1582-1587.
24. Ometto F., Botsios C., Raffeiner B., et al. Methods used to assess remission and low disease activity in rheumatoid arthritis. Autoimmun Rev 2010, 9:161-164.
25. Gossec L., Dougados M., Goupille P., et al. Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis 2004, 63:675-680.
26. Vázquez I., Graell E., Gratacós J., et al. Prognostic markers of clinical remission in early rheumatoid arthritis after two years of DMARDs in a clinical setting. Clin Exp Rheumatol 2007, 25:231-238.
27. Forslind K., Hafström I., Ahlmén M., et al. Sex: a major predictor of remission in early rheumatoid arthritis?. Ann Rheum Dis 2007, 66:46-52.
28. Mancarella L., Bobbio-Pallavicini F., Ceccarelli F., et al. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. Rheumatol 2007, 34:1670-1673.
29. Bombardieri S., Ruiz A.A., Fardellone P., et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology 2007, 46:1191-1199.
30. Rantalaiho V., Korpela M., Laasonen L., et al. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther 2010, 12:R122.
31. Hyrich K.L., Symmons D.P., Watson K.D., et al. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006, 54:1786-1794.